Question ID: WS-80
Submitted by: Society for Immunotherapy of Cancer
March 18, 2011
Recent data testing new immunotherapy approaches in advanced cancer patients have revealed remarkable clinical responses in subsets of individuals. For example, the anti-PD-1 mAb data presented at ASCO in 2010 showed a ~30 response rate in patients with melanoma, renal cell cancer, and non-small-cell lung cancer. Interestingly, these clinical responses are quite durable, even if they are not complete. As our field optimizes the combinatorial delivery of immunotherapies (e.g., vaccines plus checkpoint blockade), these exciting data raise two inter-related questions: “What predictive biomarkers can be utilized to identify patients likely to derive clinical benefit from immunotherapy? In addition, will these immunotherapies actually become curative in those patients when delivered earlier in the disease course, thus becoming first line therapies?”
| This question has not yet been evaluated by users |
Comments
